Istituto Europeo di Oncologia

Milan, Milan 20141

0 studies enrolling now · 3 studies all time

What they study most

Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, Myelofibrosis, NSCLC, Stage IB-IIIA, Ovarian Cancer, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer — Completed